First Generic vs Authorized Generic: How Timing of Market Entry Changes Everything

When a brand-name drug loses its patent, the race to sell the first generic version begins. But here’s the twist: the company that made the original drug can also launch its own generic version - and it often does, right when the first generic hits the market. This isn’t a coincidence. It’s a strategy. And it changes everything about how much money generic companies make, how low prices drop, and who really benefits.

What’s the difference between a first generic and an authorized generic?

A first generic is the first company to successfully challenge a brand-name drug’s patent and get FDA approval to sell a copy. It’s a big deal. Under the Hatch-Waxman Act of 1984, that company gets 180 days of exclusive rights to sell its version. During that time, no other generic can enter. That’s supposed to be the reward for taking the legal and financial risk of suing the brand-name maker.

An authorized generic is different. It’s made by the same company that makes the brand-name drug - or by someone they’ve licensed. It’s identical in every way: same pills, same factory, same ingredients. The only difference? It’s sold under a generic label and at a lower price. And here’s the key: it doesn’t need FDA approval as a new generic. It uses the brand’s existing approval, so it can launch in days, not months or years.

That’s the gap. First generics spend years preparing, fighting patents, and waiting for FDA review. Authorized generics? They’re ready to go the moment the brand decides to pull the trigger.

Why timing matters more than you think

The whole point of the 180-day exclusivity was to give the first generic a chance to capture the market before others jump in. Typically, they’d grab 70-90% of sales during that window. That’s where the profit is - sometimes hundreds of millions of dollars.

But if the brand company launches its own authorized generic on the same day the first generic hits shelves, everything changes. Suddenly, instead of having the market to themselves, the first generic is sharing it with the original maker. And the original maker has all the advantages: distribution networks, pharmacy relationships, brand recognition.

Research from Health Affairs shows that 73% of authorized generics launched within 90 days of the first generic’s approval. Over 40% launched on the exact same day. That’s not luck. That’s planning.

Take Lyrica, Pfizer’s nerve pain drug. When Teva launched the first generic version in July 2019, Pfizer immediately rolled out its own authorized generic through Greenstone LLC. Within weeks, Pfizer’s version captured about 30% of the generic market. Teva’s expected revenue dropped sharply. They still got their 180 days - but they didn’t get the windfall they bet on.

How this hurts price drops and consumers

Generic drugs are supposed to slash prices by 80-90%. That’s what happens when multiple companies compete to sell the same pill. But when an authorized generic enters during the first generic’s exclusivity, the price drop stalls.

RAND Corporation found that when authorized generics enter early, prices only fall 65-75%. That might sound like a lot - until you realize it’s still 15-25% higher than it would be with true competition. That difference adds up. Billions of dollars. Over time, patients pay more. Insurers pay more. Medicare pays more.

And it’s not just one drug. This happens across categories. Cardiovascular drugs, brain medications, diabetes treatments - all battlegrounds. Drugs like Eliquis and Jardiance are now seeing the same pattern: first generic launches, brand company responds with its own version, prices don’t fall as far or as fast.

Why do brand companies do this?

It’s simple: they want to keep control. Even after the patent expires, they don’t want to lose the customer. By launching their own generic, they keep a piece of the market. They don’t have to compete with unknown companies. They compete with a version of themselves.

It’s also cheaper than you’d think. No need for new clinical trials. No need to wait for FDA review. The manufacturing lines are already running. All they have to do is slap a different label on the bottle.

For brand companies, it’s a low-risk, high-reward move. For generic manufacturers, it’s a gamble that can wipe out years of investment. Some mid-sized generic firms say the window for profitable first-generic entry has shrunk to just 45-60 days in many cases. That’s not enough time to recoup costs if an authorized generic shows up.

Who wins? Who loses?

Brand companies win. They keep market share and revenue. Authorized generics sometimes get labeled as “good” because they lower prices - and they do, compared to the original brand. But compared to what the system was designed for? They’re a loophole.

The first generic companies lose. They took the legal risk, spent millions on lawsuits, waited years for approval - only to be undercut by the very company they sued.

Patients and the healthcare system lose too. Prices don’t drop as far or as fast. Savings are delayed. And because the 180-day exclusivity is meant to incentivize patent challenges, this practice weakens the whole system. Why risk $10 million to challenge a patent if the brand can just launch its own version the next day?

The Association for Accessible Medicines argues that authorized generics increase competition and speed up price drops. They point to drugs like Lipitor and Prilosec, where generics did bring down costs. But those cases were before this strategy became widespread. Today, the game has changed.

Regulators are catching on - slowly

The FDA approves about 80 first generics a year now, thanks to better funding and faster review times. But the system is still slow. The average ANDA review takes 10 months - and can stretch to three years during backlogs.

Meanwhile, authorized generics don’t even need an ANDA. They slip through the cracks.

The Inflation Reduction Act of 2022 tried to address this. It explicitly says authorized generics are not considered “generic competitors” when Medicare negotiates drug prices. That’s a big deal. It means Medicare can treat them like the brand-name drug - not as a true generic - when calculating what’s fair to pay.

The FTC has also gone after “pay-for-delay” deals, where brand companies pay generic makers to delay entry. Sometimes, those deals include promises to launch an authorized generic later. Courts have ruled those are anti-competitive. But enforcement is patchy. Many cases never get investigated.

What’s next for generic drug makers?

Generic companies aren’t sitting still. Leading firms are adapting. Some are building “dual-path” strategies: they prepare to launch both a traditional generic and an authorized generic of their own - sometimes by partnering with brand companies before the patent expires.

Others are diversifying. Instead of betting everything on one blockbuster drug, they’re building portfolios of smaller, less contested generics. That way, if one launch gets undercut, they still have others.

Some are even pushing for regulatory changes - asking the FDA to require brand companies to disclose planned authorized generic launches ahead of time. That way, first generic applicants could adjust their timing or exit the market before investing millions.

But right now, the rules still favor the brand companies. The system was built for a different time. Back then, authorized generics were rare. Now, they’re a standard tool. Evaluate Pharma predicts that by 2027, 25-30% of all generic prescriptions will be authorized generics - up from 18% in 2022.

That means the race to be first is getting harder. And the rewards? Getting smaller.